Liver and Tecfidera drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Liver (liver extract) and Tecfidera (dimethyl fumarate). Common drug interactions include fall among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Liver and Tecfidera. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Liver?

Liver has active ingredients of liver extract. eHealthMe is studying from 1,316 Liver users. Check the latest studies of Liver.

What is Tecfidera?

Tecfidera has active ingredients of dimethyl fumarate. It is often used in multiple sclerosis. eHealthMe is studying from 129,627 Tecfidera users. Check the latest studies of Tecfidera.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

29 people who take Liver and Tecfidera together, and have interactions are studied.

What are the common drug interactions of Liver and Tecfidera, by gender? *:

female:

Fall
Flushing (the warm, red condition of human skin)
Gait disturbance
Rash
Balance disorder
Headache (pain in head)
Dehydration (dryness resulting from the removal of water)
Faecal incontinence (a lack of control over passing stool)
Muscular weakness (muscle weakness)
Pruritus (severe itching of the skin)

male:

Anxiety
Ataxia (loss of full control of bodily movements)
Hypertonic bladder (bladder-storage function that causes a sudden urge to urinate)
Hypoaesthesia (reduced sense of touch or sensation)
Insomnia (sleeplessness)
Memory impairment
Micturition urgency (urgency to pass the urine)
Monoparesis (one limb is very weak, but not completely paralyzed)
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Muscle spasticity (tight or stiff muscles and an inability to control those muscles)

What are the common drug interactions of Liver and Tecfidera, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Dehydration (dryness resulting from the removal of water)
Faecal incontinence (a lack of control over passing stool)
Flushing (the warm, red condition of human skin)
Rash
Abasia (inability to walk)
Abdominal discomfort
Abdominal pain upper
Adverse reaction
Drug ineffective
Muscular weakness (muscle weakness)

40-49:

Anxiety
Ataxia (loss of full control of bodily movements)
Balance disorder
Bradycardia (abnormally slow heart action)
Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
Dizziness
Dysarthria (speech disorder)
Erectile dysfunction
Fall
Gait spastic

50-59:

Hospitalisation
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Diarrhoea
Escherichia infection (bacterial infection by escherichia coli)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Hepatic steatosis (fatty liver disease)

60+:

Adverse drug reaction
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Fall
Granuloma annulare (reddish bumps on the skin arranged in a circle or ring)
Rash
Respiratory tract congestion (blockage on respiratory system)

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 10 people, 34.48%
Gait Disturbance: 7 people, 24.14%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 13.79%

* Approximation only. Some reports may have incomplete information.

Do you take Liver and Tecfidera?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously